Any feedback?
Literature summary for 3.4.15.1 extracted from
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion (2007), Ann. Pharmacother., 41, 129-132.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | patients with hypertension due to primary aldosteronism are sometimes placed on angiotensin-converting enzyme inhibitors in accordance with guidelines applying to the general hypertensive population. The authors believe this practice is inappropriate because of the inability of angiotensin-converting enzyme inhibitors to lower blood pressure in patients with low renin levels. Pleiotropic effects of angiotensin-converting enzyme inhibitors are unlikely to provide significant benefits in the absence of blood pressure reduction. Angiotensin-converting enzyme inhibitors should be discouraged for the majority of patients with primary aldosteronism, even in face of renal or cardiac disease | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
